Description
MG Medicals, Quality Assurance
CompositionAtezolizumab
SimilarityAtezolizumab 1200mg 1s
StorageCold chain shipment
MG Medicals, Briefing of Tecentriq 1200mg 1 Injection
Uses of Tecentriq 1200mg 1 InjectionTECENTRIQ is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy.
Tecentriq 1200mg 1 Injection side reactionsImmune-Mediated Pneumonitis, Immune-Mediated Hepatitis, Immune-Mediated Colitis, Immune-Mediated Endocrinopathies, Other Immune-Mediated Adverse Reactions, Infections, Infusion-Related Reactions
How to take Tecentriq 1200mg 1 InjectionThe recommended dosage of TECENTRIQ is 1200 mg as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
How Tecentriq 1200mg 1 Injection worksMonoclonal antibody to programmed cell death ligand-1 protein (PDL1); binding PDL1 blocks the interaction between PDL-1 and its ligands. PDL1 is expressed on the surface of activated T cells under normal conditions; binding PDL1 inhibits immune activation and reduces T-cell cytotoxic activity when bound. This negative feedback loop is essential for maintaining normal immune responses and limits T-cell activity to protect normal cells during chronic inflammation. Tumor cells may circumvent T-cell–mediated cytotoxicity by expressing PDL1 on the tumor itself or on tumor-infiltrating immune cells, resulting in the inhibition of immune-mediated killing of tumor cells.
MG Medicals, More Suggestion
Suggestion for Tecentriq 1200mg 1 Injection
- Immune-related myasthenic syndrome/myasthenia gravis, Guillain Barré, or meningoencephalitis reported; permanently discontinue for any grade.
- Monitor for clinical signs and symptoms of meningitis or encephalitis; permanently discontinue treatment for any grade of meningitis or encephalitis; treat with IV steroids (1-2 mg/kg/day methylprednisolone or equivalent) and convert to oral steroids (prednisone 60 mg/day or equivalent) once patient improves; when symptoms improve to Grade ≤1, taper steroids over ≥1 month.
- Monitor for symptoms of motor and sensory neuropathy; permanently discontinue treatment for any grade of myasthenic syndrome/myasthenia gravis or Guillain-Barré syndrome; consider initiation of systemic corticosteroids at a dose of 1-2 mg/kg/day prednisone.
- Symptomatic pancreatitis without an alternative etiology occurred in 0.1% of patients across clinical trials; monitor for signs and symptoms of acute pancreatitis.
- Monitor for signs and symptoms of myocarditis.
- Thyroid disorders may occur; monitor thyroid function prior to and periodically during treatment; initiate hormone replacement therapy or medical management of hyperthyroidism as clinically indicated; continue therapy for hypothyroidism and interrupt for hyperthyroidism based on severity.
- Adrenal insufficiency may occur; monitor patients for clinical signs and symptoms of adrenal insufficiency; for Grade 2 or higher adrenal insufficiency, initiate prednisone 1-2 mg/kg/day or equivalents, followed by a taper and hormone replacement as clinically indicated; interrupt treatment based on severity.
- Type 1 diabetes mellitus reported; monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated; interrupt treatment based on severity.
- Hypophysitis/hypopituitarism may occur; for Grade 2 or higher hypophysitis, initiate prednisone 1-2 mg/kg/day or equivalents, followed by a taper and hormone replacement therapy as clinically indicated
MG Medicals, Tips & Warnings
Alcohol
There is no significant data. Please consult your doctor.
Pregnancy
caution
Based on its mechanism of action, TECENTRIQ can cause fetal harm when administered to a pregnant woman. There are no available data on the use of TECENTRIQ in pregnant women.
Lactation
There is no information regarding the presence of atezolizumab in human milk, the effects on the breastfed infant, or the effects on milk production.
Driving
There is no significant data. Please consult your doctor.
Kidney
Monitor the renal values.
Liver
May cause liver test abnormalities and immune-mediated hepatitis; fatal cases reported; monitor for signs and symptoms of hepatitis, during and after discontinuation of therapy, including clinical chemistry monitoring; administer corticosteroids, prednisone 1–2 mg/kg/day or equivalents, followed by a taper for Grade 2 or higher elevations of ALT, AST and/or total bilirubin.
MG Medicals, If miss a dose
For the best possible benefit, it is important to receive each scheduled dose of this medication as directed. If you miss a dose, contact your doctor or pharmacist right away to establish a new dosing schedule.
Disclaimer
The site and the information of MG Medicals (mgmedicals.com) are ONLY for reference purposes, and mgmedicals.com or MG Medicals or MG Medicals Pharmacy cannot be a replacement of professional medical advice, diagnosis, or treatment. MG Medicals request all visitors to obtain the advice of a physician or any qualified health provider with any questions they may have regarding a medical condition. Any prescription drugs, it’s only be sold with the approval of qualified doctors, specialists, or pharmacists.
